|
NFE2L2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.44099999499892E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.896600E-03 |
| Normal-vs-Stage2 |
1.46139988999039E-10 |
| Normal-vs-Stage3 |
1.63036251166204E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
2.862800E-01 |
| Stage1-vs-Stage3 |
1.002800E-01 |
| Stage1-vs-Stage4 |
1.674470E-02 |
| Stage2-vs-Stage3 |
2.425600E-01 |
| Stage2-vs-Stage4 |
8.121000E-03 |
| Stage3-vs-Stage4 |
2.667900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.20374887414255E-14 |
| Normal-vs-AfricanAmerican |
1.06710000002952E-06 |
| Normal-vs-Asian |
1.41050504609552E-11 |
| Caucasian-vs-AfricanAmerican |
4.086600E-01 |
| Caucasian-vs-Asian |
6.478000E-01 |
| AfricanAmerican-vs-Asian |
6.663200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.71285208239169E-12 |
| Normal-vs-Female |
3.63190000000069E-05 |
| Male-vs-Female |
2.733800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.177570E-01 |
| Normal-vs-Age(41-60Yrs) |
6.92779167366098E-14 |
| Normal-vs-Age(61-80Yrs) |
1.22124532708767E-15 |
| Normal-vs-Age(81-100Yrs) |
2.950600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.111800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.166570E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.734800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.039980E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.872800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.441400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.122500E-03 |
| Classical-VS-Follicular |
3.903400E-01 |
| Classical-VS-Other |
6.106600E-01 |
| Classical-VS-Normal |
4.68747263226987E-12 |
| Tall-VS-Follicular |
2.210400E-01 |
| Tall-VS-Other |
4.891400E-01 |
| Tall-VS-Normal |
1.64146474190829E-12 |
| Follicular-VS-Other |
3.307600E-01 |
| Follicular-VS-Normal |
4.966200E-01 |
| Other-VS-Normal |
7.204200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.782800E-03 |
| Normal-vs-N1 |
1.63880020664919E-12 |
| N0-vs-N1 |
1.455620E-01 |
|
|
